drugset / Trial / NCT04791878

Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease

NCT04791878

Phase 1 Terminated 6 enrolled Anthony Lembo
NaSingle-groupOpen-labelTreatment

Summary

This study plans to enroll 10 patients aged 13-17 years of age with refractory perianal fistulizing disease. Patients will be treated by direct injection to the fistula tract(s) with 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed.

Timeline

Start
2021-04-01
Primary completion
2023-11-01
Completion
2023-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 7.5e+07 cells Other